Explore published research on genetics, including study methods and limitations.
In nearly 2,000 female twins, whether someone tried cannabis was shaped by environment, but progression to heavy use and dependence was 62-79% heritable, driven primarily by genetics.
In 1,198 male twin pairs, trying cannabis was influenced by family environment, but heavy use and dependence were 60-80% genetic, mirroring identical findings in female twins.
Twin study of 3,360 male pairs finding that the genetic link between depression and cannabis/alcohol dependence was largely explained by shared genetic risk for antisocial personality disorder.
A nationally representative US twin study found cannabis use in the past year was at least 60% heritable, with identical twins much more similar than fraternal twins or siblings.
Twin study of 2,125 pairs finding cannabis-other drug comorbidity is best explained by shared genetic and environmental risk factors rather than gateway causation.
Twin study finding cannabis dependence linked to 2.5-2.9x higher suicide risk even after controlling for shared genetics, while the depression link was explained by shared genetic vulnerability.
Review of twin and family studies found a genetic basis for every stage of cannabis involvement, with some genetic risk factors shared across cannabis, alcohol, tobacco, and other drugs.
Norwegian twin study found genetic factors accounted for 58-81% of variation in illicit drug use and dependence, replicating findings from higher-prevalence countries like the US and Australia.
Large twin study found common genetic factors drive adolescent problem use across tobacco, alcohol, and marijuana, while shared environmental factors drive experimentation but not progression to problems.
Twin study of 1,088 pairs found that childhood conduct problems contributed a small but significant genetic risk to marijuana use 8 years later, suggesting shared genetic vulnerability.
Genome-wide scan of high-risk families found overlapping chromosomal regions linked to both alcohol and cannabis dependence, particularly on chromosomes 2 and 10, suggesting shared genetic vulnerability.
Review mapped the genetics of cannabis disorders: linkage regions on seven chromosomes and candidate genes in both the cannabinoid system (CNR1, FAAH, MGLL) and general addiction pathways.
Twin study developed a 50% heritable alcohol consumption measure that correlated with cannabis and nicotine use, supporting shared genetic vulnerability across substances.
Among 464 cannabis users from a twin-family study, those who experienced stronger subjective effects were 3-12 times more likely to become heavy users, even after controlling for genetic risk.
In 37 abstinent cannabis users, genetic variants in CNR1 and FAAH genes were associated with greater brain reward-area activation when viewing marijuana cues, with an additive effect of risk alleles.
In 169 first-episode psychosis patients, cannabis use was linked to earlier onset and appeared to override the COMT gene's protective delay effect.
Twin study of 6,257 people found genetics explain over 60% of cannabis use and dependence variation, with substantial genetic overlap with alcohol.
Meta-analysis of 28+ twin studies found genetics explained 40-48% of cannabis initiation and 51-59% of problematic use, with environment more influential for initiation.
Dutch twin study found 44% heritability for cannabis initiation, matching results from countries with stricter cannabis laws.
First GWAS of cannabis dependence tested nearly 1 million genetic variants in 3,054 people, finding suggestive signals but no definitive genetic associations.
In 7,753 Dutch twins/siblings, cannabis initiation heritability was 40% at age 16.5, with environmental influences growing with age, especially factors shared between twins.
A cannabinoid receptor gene variant influenced how THC affected attention-related brain waves, with CBD in cannabis extract appearing to buffer the effect.
Twin study of 5,638 found the link between borderline personality and cannabis use is genetically driven, while the alcohol connection is environmental.
Preliminary study found a serotonin receptor gene variant influenced brain activation patterns after cannabis treatment in adolescents.
Large Australian twin study found 72-80% heritability for cannabis use, early onset, and abuse/dependence, among the highest for any substance.
Twin study found over 60% of the shared vulnerability to alcohol, tobacco, and cannabis dependence was driven by common genetic factors.
Adolescent THC exposure in rats altered gene regulation through epigenetic changes in the reward system, directly increasing vulnerability to heroin self-administration.
A study of 7,452 twins found none of 10 previously reported cannabis-associated genes replicated, suggesting earlier findings were likely false positives.
Twin study found shared genetic risk for nicotine, alcohol, and marijuana peaked at ages 14-17 and declined into adulthood as substance use became more environmentally driven.
Children of substance-using parents showed reduced error-processing brain activity even before any cannabis use, suggesting an inherited vulnerability marker.
Twin study found a common genetic factor drove vulnerability to alcohol, tobacco, and cannabis dependence, with genetic influence increasing from 43% to 63% through adolescence.
Twin study found cannabis withdrawal was about 50% heritable, with 99% overlap between genes influencing withdrawal and those influencing abuse/dependence.
A genome-wide analysis of over 10,000 people found no single gene strongly linked to cannabis use initiation, with common variants explaining only about 6% of variation.
Twin study found that initial reactions to tobacco predicted both nicotine and cannabis dependence, while cannabis reactions predicted only cannabis outcomes, with 27-35% heritability for first-use reactions.
A specific AKT1 gene variant determined whether THC impaired psychomotor control, with carriers showing increased errors and reduced brain activation in a motor control region.
In 3,080 twins, both ADHD symptoms and autistic traits independently predicted cannabis use disorders, while autistic traits showed a paradoxical pattern of less alcohol use but higher dependence risk.
Unexposed offspring of THC-exposed rats showed compulsive heroin-seeking behavior and altered striatal brain circuitry, suggesting transgenerational epigenetic effects of parental cannabis exposure.
Mice with a genetic variant in neural cell adhesion showed delayed but lasting cognitive damage from juvenile THC exposure, while normal mice did not, supporting a gene-environment interaction.
Study of 463 adolescents found COMT gene methylation was linked to smoking, and a specific genotype-methylation interaction influenced high-frequency cannabis use.
Mice with a schizophrenia-linked gene mutation showed worsened emotional memory and reduced brain activity when exposed to THC during adolescence, demonstrating gene-environment interaction.
Adolescent THC exposure affected heroin reward differently in addiction-prone vs. resilient rat strains, suggesting genetics determine whether cannabis acts as a gateway.
Review of schizophrenia etiology identified cannabis use as one of the two most important environmental risk factors, interacting with genetic vulnerability through epigenetic mechanisms.
Swedish study of nearly 80,000 twin and sibling pairs found that 75-90% of genetic risk for drug abuse is shared across cannabis, stimulants, and sedatives rather than being drug-specific.
Study of nine Cannabis sativa varieties found cold-hardy types activated specific genes and epigenetic changes during cold acclimation that less hardy varieties could not.
Genetic analysis of 2,596 people found common gene variants explain 25-36% of drug dependence vulnerability, with genetic effects almost entirely shared across substances.
Twin study of nearly 10,000 teens found the cannabis-psychotic experience association is driven by shared environmental factors (69-100%) rather than genetics, with cannabis explaining only 2-5% of psychotic experience variance.
Adolescent THC exposure in rats produced over 1,000 regions of altered DNA methylation in their unexposed offspring's brain reward center, affecting glutamatergic signaling genes.
A review of animal research found that prenatal cannabinoid exposure can produce lasting immune dysfunction in offspring through epigenetic mechanisms like altered DNA methylation and microRNA.
Genetic risk scores for schizophrenia predicted cannabis and cocaine involvement, while depression genetic risk predicted cannabis use and severe cocaine dependence, in 2,573 participants.
A CNR1 gene variant moderated how much nicotine withdrawal disrupted brain function, with some genetic profiles showing greater cognitive disruption during deprivation.
A study of nearly 10,000 Australian twins found that while lifetime cannabis use and self-injury share genetic roots, early cannabis use before age 17 appears to carry independent risk for self-harm even after accounting for genetics.
Controlled trial shows cannabis and cocaine increase impulsivity and reduce brain connectivity, but only in people with a genetic variant predisposing to higher dopamine levels.
Largest cannabis GWAS (32,330 people) identified four genes and found genetics explain 13-20% of cannabis use variation, with 83% genetic overlap with cigarette smoking.
Review finds cannabis can alter epigenetic marks controlling gene expression in brain and body, with emerging evidence suggesting some changes may pass to offspring.
In identical twin pairs, the twin who used cannabis frequently was about twice as likely to have depression and 2.5 times as likely to report suicidal thoughts, even after controlling for shared genetics.
A variant in the cannabinoid receptor gene CNR1 was linked to more frequent cannabis use at age 18, but the genetic effect did not change the trajectory of use over the following six years.
Study of 804 neonates found no strong evidence that maternal cannabis use during pregnancy alters DRD4 dopamine receptor gene methylation in infants.
Study of 61 schizophrenia patients finding those with heavy pre-psychosis cannabis use had fewer neurological signs and better cognitive function, suggesting cannabis-associated psychosis may be a distinct disease subtype.
Study of 260 first-episode psychosis patients finding early cannabis use and BDNF met-allele independently predicted younger psychosis onset, with early cannabis use more common in males.
Twin study of 2,793 young adults finding the cannabis-psychosis link is explained by shared genetics (55% correlation) plus a direct effect from cannabis use disorder to psychotic experiences, not the reverse.
Case-control study found that adolescents with first-episode psychosis and a family history of psychosis actually had milder positive symptoms at onset, challenging assumptions about genetic risk.
Patients with psychosis who used cannabis heavily before illness had higher schizophrenia polygenic risk scores, with the largest effect in those who started before age 18.
Brain imaging of 59 young men found early cannabis use altered hippocampal subregion volumes, with effects modified by the DAT1 dopamine transporter gene variant.
Umbrella review of 98 associations found only five truly robust risk factors for schizophrenia: childhood adversity, cannabis use, obstetric complications, adult stress, and low folate.
Review of 13 studies found that COMT and other dopamine-related gene variants modulate how cannabis impairs working memory, attention, and other cognitive functions.
Twin study of 3,762 adolescents found childhood ADHD predicted earlier marijuana use, but identical twin analysis indicated shared genetics, not ADHD itself, primarily drive the link.
Case-control study found a CB1 receptor gene variant associated with cannabis use and higher DNA methylation at dopamine receptor genes in users, plus protective effects of education and female sex.
Longitudinal study found higher schizophrenia genetic risk predicted stronger cannabis use increases during ages 16-20, with no relationship to alcohol or tobacco, supporting shared genetics between schizophrenia and cannabis use.
Twin study found cannabis use disorder is 78% heritable, but 83% of genetic risk overlaps with genes affecting opportunity and frequency of use, with only 17% unique to the disorder.
Selective breeding study found adolescent THC sensitivity in mice was heritable and genetically linked to anxiety-like behavior, pointing to shared genetic factors between cannabis response and anxiety.
Largest GWAS of cannabis initiation timing found 38% heritability and identified ATP2C2 (calcium signaling gene) as a candidate, linking cannabis initiation to the same pathway implicated in cocaine and opioid dependence.
Cannabis use altered DNA methylation at nearly 4,000 sites in human sperm, affecting Hippo Signaling and cancer pathways. Same pathways were affected in THC-exposed rat sperm, and changes overlapped with offspring brain methylation.
Review of 66 studies concluded cannabis doubles psychosis risk in vulnerable individuals, with dose-response and age-of-first-use effects, and gene-environment interactions modulating individual susceptibility.
Largest cannabis GWAS (184,765 people) found 8 significant variants, CADM2 as the top gene, 11% heritability, and Mendelian randomization evidence that schizophrenia risk causally increases cannabis use.
Review reveals that cannabis exposure during development can create lasting epigenetic changes - modifications to gene expression that persist across the lifespan and have been observed transmitting to the next generation.
In a mouse MS model, THC plus CBD together (but not alone) reduced paralysis and brain inflammation by suppressing inflammatory immune cells and altering microRNA gene regulation.
Cannabis users with two copies of a specific FAAH gene variant had 10x higher odds of a first psychotic episode, identifying a gene-environment interaction that could explain selective psychosis risk.
THC increased brain activity in attention and salience networks, with the COMT gene variant determining how executive networks responded, linking dopamine genetics to cannabis susceptibility.
Genome-wide study of over 350,000 people identifies CHRNA2, a nicotinic receptor gene, as the first replicated genetic risk factor for cannabis use disorder, linking it to cholinergic and cognitive pathways.
Review exploring how combined alcohol and cannabis exposure alters gene activity through epigenetic mechanisms across different life stages, with potential for lasting and even intergenerational effects.
Study of 500 college students finds the MAOA gene interacts with childhood abuse to predict cannabis and tobacco use in sex-opposite patterns: high-activity variants matter in women, low-activity in men.
Twin study of 2,007 young adults finds non-medical painkiller misuse shares moderate genetic overlap with cannabis and nicotine use, but minimal overlap with cannabis or alcohol use disorders.
Review finds the cannabis-schizophrenia causal hypothesis remains unproven after decades of research, with three competing explanations and significant gaps in social, cultural, and non-Western evidence.
Mouse study shows paternal cannabinoid (CB2) exposure alters sperm DNA methylation and reduces offspring growth through epigenetic changes transmitted in sperm to the placenta.
Mouse study shows adolescent THC only caused lasting memory impairment when combined with genetic vulnerability in astrocytes (support cells), operating through an inflammatory pathway blockable by a COX-2 inhibitor.
Paternal THC exposure in rats (modest dose, 12 days) caused long-lasting attention impairments in offspring, likely through epigenetic changes in sperm.
Adolescent THC caused premature dendritic pruning and altered gene networks in rat PFC neurons, with dysregulated networks overlapping schizophrenia-associated pathways.
COMT Val/Val carriers were most vulnerable to THC-induced cognitive deficits. A COMT inhibitor reduced these effects, but THC's psychosis-like effects were independent of dopamine.
Cannabis use alters DNA methylation in human sperm, potentially affecting offspring development and possibly future generations through epigenetic inheritance.
A cannabinoid receptor gene variant (CNR1 rs7766029) predicted cognitive improvement over 18 months in first-episode psychosis patients.
A genome-wide study found a P2RX7 gene variant associated with psychotic experiences in cannabis users, replicated in a second cohort. THC and CBD affected the P2X7 receptor differently depending on genotype.
THC interacts with common medications through shared liver enzymes (CYP3A4, CYP2C9), and genetic variants in up to 35% of Caucasians increase THC bioavailability.
A mouse model of a human FAAH gene variant showed that adolescent females had enhanced dopamine reward circuitry and stronger THC preference that lasted into adulthood, while males were unaffected.
Specific nicotinic receptor subtypes (alpha3beta4, alpha6beta4) modulated THC withdrawal in mice, with human genetic variants in the same genes associated with cannabis disorder, identifying new medication targets.
Study comparing 201 cannabis-dependent patients to 285 controls found specific methylation differences at dopamine transporter gene sites bound by nervous system development transcription factors.
Rat study found offspring of THC-exposed fathers showed hyperactivity and cognitive deficits despite mothers never being exposed, suggesting paternal cannabis use before conception can affect offspring.
Largest GWAS meta-analysis of cannabis use disorder (384K participants) identified 22 risk loci, 11% SNP heritability, and strong genetic overlap with ADHD, depression, and schizophrenia.
Landmark GAP study of 410 first-episode psychosis patients found 25% of new cases attributable to high-potency cannabis, with genetic and environmental factors acting together.
In 3 infants with rare KCNT1 epilepsy, CBD showed limited benefit: 2 had no response, 1 had reduced seizure intensity and possible developmental progress.
Mouse study found CBD produced antidepressant effects by normalizing stress-induced DNA methylation changes in prefrontal cortex and hippocampus.
PNAS study found adolescent cannabinoid exposure reprogrammed the rat brain response to cocaine at epigenomic, transcriptomic, and proteomic levels, specifically during adolescence.
THC altered DNA methylation at 7 neurodevelopmental genes in rat sperm, overlapping with nicotine effects and enriched for autism candidate genes.
Cannabis use linked to widespread methylation changes in autism gene DLGAP2 in human sperm, with similar changes found in rat offspring brains after paternal THC exposure.
Molecular Psychiatry study found ADHD genetically causes 8-fold increased cannabis use risk (OR 7.9), with 29% genetic overlap and 4 new shared loci identified.
Postmortem brain study found CB1 receptor expression is highest fetally, drops after birth, is decreased in schizophrenia, and follows a COMT-genotype-dependent trajectory.
Cannabis use and subclinical psychosis traits showed consistent positive correlations in the general population, with one significant genetic link: social anhedonia was inversely correlated with cannabis use frequency.
Two weeks of daily CBD altered DNA methylation at 3,323 sites in mouse hippocampus, affecting genes linked to neural development and psychiatric conditions.
Genetic analysis of 11 psychiatric disorders found cannabis use disorder was significantly correlated only with ADHD, while alcohol and nicotine dependence showed broad genetic overlap with multiple psychiatric conditions.
A longitudinal study found an epigenetic biomarker (cg05575921 methylation) detected both tobacco and cannabis smoke exposure in high school students, distinguishing combusted from non-combusted products.
In a controlled THC study of 36 men, both a genetic variant (AKT1 rs1130233) and DNA methylation independently influenced how THC affected fear-related brain activity, with the epigenetic state partially mediating the genetic effect.
A study of 703 adolescents found cannabis use linked to specific DNA methylation changes in immune cells. Notably, patterns in T cells and monocytes overlapped with brain tissue findings from psychosis research.
Analysis of 3,785 Australian twins found five drug use patterns, with persistent polydrug use showing 94% heritability and links to conduct and antisocial personality disorders.
Study of 2,051 European teens found endocannabinoid gene interactions (CNR1, MGLL, DAGLA) associated with alcohol use disorder risk, with partial replication in 772 Canadian adolescents.
Study of 318 IVF follicular fluid samples found cannabis exposure altered cannabinoid receptor and DNA methylation enzyme expression in granulosa cells, with cannabis detection tripling after Canadian legalization.
Adolescent cannabinoid exposure in mice reduced cocaine reward in adulthood and increased a DNA methylation enzyme in the prefrontal cortex, without affecting anxiety or depression.
Twin study of 436 young adults found alcohol misuse was associated with thinner cortex in cognitive control brain regions, reflecting both genetic predisposition and direct exposure. Cannabis showed no such effects.
Genomic analysis found significant genetic overlap between cannabis use disorder vulnerability and COVID-19 hospitalization risk, independent of tobacco, alcohol, or respiratory disease genetics.
Study of 88,637 individuals found genetic risk for schizophrenia did not predict cannabis use disorder, while genetic risk for ADHD did, challenging the shared-genetics hypothesis for the cannabis-schizophrenia link.
Mice with reduced Reelin protein showed worse social, behavioral, and stress outcomes after adolescent THC exposure than normal mice, suggesting genetic factors influence cannabis vulnerability.
Study of 50 treatment-resistant schizophrenia patients found THC consumers had nearly double the DNA methylation in the NRXN1 gene promoter compared to non-consumers, suggesting epigenetic links between cannabis and psychosis.
Mendelian randomization found genetic liability to bipolar disorder increased cannabis use risk, but genetic liability to cannabis use did not increase bipolar disorder risk, suggesting a self-medication pathway.
Large genetic study found cannabis use disorder (but not simply trying cannabis) was robustly associated with schizophrenia risk after controlling for tobacco, with mixed evidence on whether the relationship is causal.
Two experiments with 1,601 young adults found that learning about genetic predisposition for cannabis-related psychosis risk increased intentions to avoid marijuana, especially among prior users.
The first blood-based epigenome-wide study of cannabis use identified a replicated DNA methylation marker in the CEMIP gene, though its ability to predict cannabis use history was modest.
A large genetic study found significant positive correlations between anorexia nervosa and both cannabis initiation and cannabis use disorder, with substance-specific patterns suggesting complex shared biology.
Large EU-GEI study finds genetic schizophrenia risk and daily cannabis use independently contribute to positive psychotic symptoms in both patients and healthy controls.
Study of 1,544 twins found that while cannabis use was associated with higher psychoticism scores, within-twin-pair comparisons showed no causal effect, suggesting shared genetics explain the link.
Study found that cannabis-related DNA methylation changes in sperm, concentrated at developmental genes, were significantly diminished after 77 days of abstinence, suggesting reversibility.
Umbrella review found that while many risk factors for substance use disorders were statistically significant, only antisocial behavior had convincing evidence for predicting cannabis use disorder (OR=3.34).
Mendelian randomization found causal pathways from ADHD liability to smoking and cannabis initiation, but not convincingly in reverse, suggesting ADHD drives substance use rather than vice versa.
Genetic analysis of 989 ADHD patients and population GWAS data confirmed shared genetic architecture between ADHD and substance use disorders, with evidence ADHD causally increases SUD risk.
Among 109,308 UK Biobank participants, cannabis use was strongly linked to psychotic experiences, with people in the top fifth of schizophrenia genetic risk showing nearly 10 times the effect size compared to those in the bottom fifth.
First study of developmental CBD exposure found mice exposed in utero and during nursing showed increased anxiety and thousands of brain DNA methylation changes as adults, despite known benefits of direct CBD exposure.
Mendelian randomization found no broad causal link between cannabis use and cardiovascular disease, but after adjusting for tobacco and BMI, possible small effects on small vessel stroke (17% increase) and atrial fibrillation (6% increase) emerged.
A review details how DNA methylation, histone changes, and RNA networks regulate cannabinoid receptor expression in health and disease.
A review warns that cannabis exposure in autistic individuals may increase psychosis risk through epigenetic effects on shared genetic pathways, with potential intergenerational consequences.
A genetic analysis found cannabis use disorder was independently linked to higher risk of atrial fibrillation, heart failure, pulmonary embolism, and stroke, beyond traditional cardiovascular risk factors.
A study of 515 men found cannabis-dependent individuals had distinct personality profiles and a different frequency of the DRD2 rs1799732 dopamine receptor gene variant.
Research suggests CBD may work partly by changing DNA methylation patterns, offering a new explanation for its broad effects on anxiety, depression, and psychosis.
First study of its kind found cannabis exposure altered DNA methylation at 3,679 sites in human ovarian follicle cells, some in a dose-dependent manner.
UK Biobank genetic analysis found cannabis lowers eye pressure through the GAS7 gene in humans, while the receptors responsible in mice (CB1, GPR18) are not involved in people.
Cross-referencing cannabis methylation studies with depression genetics found multiple depression-associated genes are epigenetically regulated by cannabis, suggesting a molecular mechanism for the cannabis-depression link.
Among 3,205 substance-naive children, higher genetic risk for lifetime cannabis use was associated with better cognitive scores, suggesting shared genetic overlap with traits like curiosity rather than a cannabis benefit.
JAMA Psychiatry study found bipolar II and cannabis use disorder cluster in families. Mood episodes typically preceded CUD, suggesting shared vulnerability and a potential prevention target.
Genetics study found shared genetic links between brain cortical structure and substance use behaviors, with cannabis use genetics correlating with insula surface area differences.
First genomic study of CHS found patients carried significantly more mutations in COMT, TRPV1, CYP2C9, DRD2, and ABCA1 genes, potentially explaining why some heavy users develop CHS while others do not.
Lab model of human sperm development showed cannabis exposure altered DNA methylation at autism-linked and imprinted genes.
First whole-genome sperm methylome study of cannabis exposure found 3,321 altered sites in rats, with changes detectable in offspring and associated with heart enlargement.
Study of 24 cannabis users found smoking high-THC cannabis changed DNA methylation enzyme levels in blood cells within hours, a potential link to psychosis risk.
Genome-wide study of 780,000+ people found shared genetic factor explaining 8.6% of schizophrenia risk, highlighting NCAM1 as a key gene linking smoking, cannabis, and psychosis.
Small study of 18 adolescents found chronic cannabis use linked to DNA methylation changes at six sites that statistically mediated lower verbal memory scores.
Mouse study found adolescent THC exposure changed brain gene networks differently by sex, with four key driver genes also linked to human cannabis use disorder vulnerability.
Study found clinical psychosis risk youth had elevated cannabis, alcohol, and tobacco use, while genetically at-risk youth (22qDel) had lower rates, with social and cognitive factors explaining the difference.
Study of 3,424 adults found alcohol altered 2,569 DNA methylation sites and tobacco 528, but marijuana showed no significant changes, with alcohol-related methylation mediating hypertension risk.
Genetic analysis found cannabis use disorder may reduce education by 1.2 months, while higher education was associated with more lifetime cannabis use but 61% lower disorder risk.
Lancet Psychiatry study found significant genetic overlap between cannabis use and schizophrenia/bipolar disorder, with evidence of causal effects running in both directions.
A longitudinal study of 1,000+ adults found marijuana use was associated with DNA methylation changes in genes related to schizophrenia, bipolar disorder, cell proliferation, and hormone signaling.
Review argues epigenomic evidence links cannabis exposure to birth defects, cancer, and accelerated aging through DNA methylation disruption across generations.
In 249 first-episode psychosis patients, polygenic risk scores for cannabis use predicted symptom trajectories, suggesting partially independent genetic factors for initiation vs. disorder.
Macaque study found prenatal THC edible exposure changed DNA methylation at autism-linked genes, with 98% of changes occurring in placenta.
Two large studies found daily high-potency cannabis use carried 5x psychosis risk independently of genetic predisposition, and schizophrenia genetics did not predict heavy cannabis use.
A CB2 cannabinoid receptor genetic variant was associated with 61% lower odds of priapism in sickle cell anemia patients — connecting the endocannabinoid system to blood vessel complications.
Psychotic subjects showed elevated DNA methylation at cannabinoid and dopamine receptor genes compared to controls, but active THC use reversed these changes, complicating their potential as biomarkers.
A trans-ancestry epigenome study of 9,436 people identified four DNA methylation sites linked to cannabis use independent of smoking, with an additional site found in never-smokers.
Genomic analysis found cannabis use disorder has causal genetic effects on opioid, alcohol, and nicotine disorders, with bidirectional influences. CUD and simple cannabis use are genetically distinct.
EWAS in 2,310 veterans found four DNA methylation sites linked to cannabis use disorder independent of smoking, with the CUD-PTSD combination producing amplified epigenetic changes beyond either condition alone.
A scoping review found that cannabis exposure alters DNA methylation at genes tied to dopamine signaling, neurodevelopment, and cell survival, with links to psychiatric symptoms.
Five genetic mutations have been identified that distinguish CHS patients from asymptomatic heavy cannabis users, affecting THC metabolism, dopamine signaling, and the TRPV1 receptor.
Genetic analysis of 200,000+ individuals found cannabis use disorder and schizophrenia share genetic roots — polygenic liability for each independently predicted the other condition.
European longitudinal study finds genetic risk for cannabis use disorder is associated with impulsivity, novelty seeking, and white matter brain changes as early as age 14.
A meta-analysis of 682 participants found cannabis use was associated with specific DNA methylation changes at immune and mitochondrial genes, independent of tobacco, with evidence that psychosis status may modify how cannabis affects the epigenome.
Males with a specific MAOA gene variant who experienced childhood sexual abuse were more likely to use cannabis for coping, but this combination was associated with lower aggression.
In 4,808 adolescents, genetic predisposition to sensation seeking predicted early substance and alcohol use by age 15, while no impulsivity-related genetic scores predicted cannabis initiation specifically.
Small study of 58 pain patients found a dopamine-related gene variant significantly influenced THC blood levels, with biomarker differences between inhaled and oral cannabis routes.
The Dunedin Study found long-term cannabis users have distinct DNA methylation patterns, suggesting lasting epigenetic effects from decades of use.
Genetic study finds leisure screen time increases cannabis use disorder risk by 43%, with smoking initiation mediating over half the effect. Sedentary desk work was protective.
A study of 120 Iraqi subjects explored whether cannabinoid receptor gene variants influence kidney disease in diabetes—finding novel variants but no significant clinical associations.
A study of 240 Iranians found that a genetic variant in the cannabinoid CB2 receptor gene was associated with more than 2.5 times the risk of developing rheumatoid arthritis.
A review proposes that cannabis may trigger psychosis in genetically vulnerable individuals by disrupting glutamate signaling in the brain's default mode network, and outlines how to test this hypothesis.
Two longitudinal studies found prenatal cannabis exposure was linked to DNA methylation changes in neurodevelopment genes, persisting from birth through age 27 across two countries.
A study of 731 18-year-olds found parent cannabis use predicted offspring use, but positive parenting in early childhood significantly buffered against cannabis use disorder symptoms.
Twin study of 3,165 adults found cannabis use for sleep linked to worse sleep quality and more substance use, even after controlling for shared genetics.
Systematic review of 38 studies finds high-potency cannabis, genetic predisposition, and environmental stressors interact to drive psychotic-like experiences in otherwise healthy people, with evidence of a bidirectional relationship.
Study of 573 psychosis cases found genetic and environmental risks (including cannabis) act independently, with schizophrenia-spectrum disorders driven more by genetics and affective psychosis by environment.
Small study found FAAH, the enzyme that breaks down endocannabinoids, is specifically altered in chronic migraine patients, with changes correlating to headache severity and psychiatric symptoms.
A genetic variant in the cannabinoid receptor 1 gene (rs1049353) differed in frequency between cannabis users who developed psychosis and those who didn't.
Review of molecular, clinical, and forensic evidence shows cannabinoids can disturb cardiac electrophysiology and unmask hidden genetic heart rhythm disorders, potentially causing fatal arrhythmias.
Study of 1,017 African American youth found polygenic risk scores for cannabis disorder did not predict cannabis initiation age, and parental monitoring interacted with genetic risk in unexpected ways.
Longitudinal sibling study of 1,261 high-risk adolescents found cannabis use was not associated with suicidal thoughts or behaviors after controlling for shared genetic and environmental influences.
Mendelian randomization study found no causal link between cannabis use disorder and any cancer type, while opioid use disorder showed potential associations with bladder cancer and leukemia.
Study of 490 males found cannabis use disorder associated with altered DAT1 dopamine gene methylation, which correlated with higher neuroticism and anxiety, suggesting epigenetic pathways for cannabis's psychological effects.
Genomic analysis of 30,000+ individuals found genetic variants influence endocannabinoid system gene expression in tissue-specific patterns, explaining why cannabinoid responses vary between individuals.
Among 71 older cannabis users, 86% had genetic variants altering cannabinoid metabolism—explaining why the same dose affects people so differently.
Largest cannabis genetics study (N=258,823) finds 11 variants linked to trying cannabis, prominently CADM2, with genetics of experimentation distinct from addiction and overlapping with risk-taking.
Genomic analysis reveals education and cannabis share 84% of causal genetic variants, but in opposite directions — genes promoting education also promote trying cannabis while protecting against cannabis use disorder.
Machine learning models predicted cannabis use disorder progression with 74% accuracy using the All of Us cohort, with demographics and income being the strongest predictors.
Endocannabinoid system genes traced back 500+ million years across the animal kingdom — proving the ECS is among the most ancient and essential signaling systems in biology.
The comprehensive review that argued the gateway hypothesis should be replaced by the common liability model: shared genetic and neurobiological risk factors, not cannabis itself, drive drug escalation.
The Australian twin study that provided the strongest evidence for a cannabis gateway effect: early-using twins were 2-5x more likely to escalate to other drugs.